Chimerix, Inc. (NASDAQ:CMRX) Given Consensus Recommendation of “Hold” by Analysts

Chimerix, Inc. (NASDAQ:CMRXGet Rating) has been given a consensus recommendation of “Hold” by the six brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $9.00.

CMRX has been the topic of a number of recent research reports. StockNews.com cut shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Saturday, April 16th. Maxim Group reduced their price target on shares of Chimerix to $6.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th. Wedbush reaffirmed an “outperform” rating on shares of Chimerix in a research report on Monday, May 16th. Zacks Investment Research raised shares of Chimerix from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Cowen reduced their price target on shares of Chimerix to $10.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th.

Shares of CMRX traded down $0.54 during mid-day trading on Tuesday, hitting $1.81. The company had a trading volume of 9,768,812 shares, compared to its average volume of 2,101,845. The business’s 50-day simple moving average is $4.39 and its 200-day simple moving average is $5.39. The company has a quick ratio of 3.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.01. Chimerix has a 1-year low of $1.57 and a 1-year high of $9.29. The stock has a market cap of $158.26 million, a PE ratio of -1.57 and a beta of 1.28.

Chimerix (NASDAQ:CMRXGet Rating) last released its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. Chimerix had a negative net margin of 17,994.28% and a negative return on equity of 118.41%. During the same period in the previous year, the firm earned ($0.18) EPS. On average, sell-side analysts expect that Chimerix will post 1.58 earnings per share for the current year.

In other news, CFO Michael T. Andriole bought 15,000 shares of Chimerix stock in a transaction dated Tuesday, May 17th. The shares were acquired at an average cost of $1.71 per share, with a total value of $25,650.00. Following the completion of the transaction, the chief financial officer now owns 212,724 shares in the company, valued at approximately $363,758.04. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have bought 36,400 shares of company stock worth $65,234. Corporate insiders own 6.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Philosophy Capital Management LLC bought a new stake in shares of Chimerix in the first quarter worth $2,888,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Chimerix in the first quarter worth $66,000. Goldman Sachs Group Inc. increased its stake in shares of Chimerix by 45.1% in the first quarter. Goldman Sachs Group Inc. now owns 749,092 shares of the biopharmaceutical company’s stock worth $3,431,000 after buying an additional 232,839 shares during the last quarter. State Street Corp increased its stake in shares of Chimerix by 14.2% in the first quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock worth $20,893,000 after buying an additional 568,498 shares during the last quarter. Finally, Prelude Capital Management LLC increased its stake in shares of Chimerix by 43.6% in the first quarter. Prelude Capital Management LLC now owns 144,917 shares of the biopharmaceutical company’s stock worth $664,000 after buying an additional 44,033 shares during the last quarter. 62.76% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix (Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Featured Articles

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.